ALEX vs FOR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Despite strong historical price performance and a high dividend yield, the company faces significant headwinds with declining revenue and earnings, poor liquidity ratios, and negative insider sentiment. Valuation metrics appear stretched relative to fundamentals, particularly with a forward P/E of 34.02 amid negative growth. The stock trades above both the Graham Number ($17.77) and intrinsic value estimate ($7.07), suggesting overvaluation absent a turnaround.
Forestar Group Inc. presents a compelling value opportunity, characterized by a stable Piotroski F-Score of 4/9 and a significant discount to its Graham Number ($50.9) and Intrinsic Value ($96.76). The company maintains an exceptionally clean balance sheet with a Debt/Equity ratio of 0.17 and a healthy Current Ratio of 1.91. While YoY revenue growth is slightly negative (-3.00%), earnings growth remains robust at 22.30%, suggesting improved operational efficiency. Despite a bearish technical trend (10/100), the fundamental valuation metrics (P/E 8.57, P/B 0.80) indicate the stock is deeply undervalued.
Compare Another Pair
Related Comparisons
ALEX vs FOR: Head-to-Head Comparison
This page compares Alexander & Baldwin, Inc. (ALEX) and Forestar Group Inc. (FOR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.